{
    "type": "VariantTherapeuticResponseProposition",
    "predicate": "sensitivity",
    "description": "As a single agent or in combination with ipilimumab, for the treatment of adult and pediatric patients 12 years and older with microsatellite instability-high (MSI-H) or mismatch repair deficient (dMMR) metastatic colorectal cancer (CRC) that has progressed following treatment with a fluoropyrimidine, oxaliplatin, and irinotecan",
    "geneContextQualifier": "--",
    "objectTherapeutic": "Nivolumab [Opdivo]"
}